<div class="at-above-post addthis tool" data-url="https://www.metro.us/switzerland-unfortunately-still-awaiting/"></div>ZURICH (Reuters) – Switzerland’s drug regulator is still awaiting data needed to consider whether to approve AstraZeneca’s COVID-19 vaccine, a Swissmedic official said on Tuesday, adding the information “unfortunately” had yet to be submitted. AstraZeneca was the first vaccine maker to seek Swiss approval in early October 2020, but has since been overtaken by three […]<! AddThis Advanced Settings above via filter on get the excerpt ><! AddThis Advanced Settings below via filter on get the excerpt ><! AddThis Advanced Settings generic via filter on get the excerpt ><! AddThis Share Buttons above via filter on get the excerpt ><! AddThis Share Buttons below via filter on get the excerpt ><div class="at-below-post addthis tool" data-url="https://
By Syndicated Content
Apr 20, 2021 7:47 AM
ZURICH (Reuters) - Switzerland s drug regulator is still awaiting data needed to consider AstraZeneca s COVID-19 vaccine candidate for approval, a Swissmedic official said on Tuesday, adding the information unfortunately has yet to be submitted. We re waiting, just like the U.S. Food and Drug Administration, for the results of clinical trials in Latin America and North America, Claus Bolte, Swissmedic s head of approvals said at a virtual press conference from Bern. It was announced four weeks ago, but it has unfortunately not yet been submitted.
(Reporting by John Miller, editing by John Revill) ); } return false;
Coronavirus latest news: UK getting safer every day as almost 1 in 5 adults have had first vaccine, says Nadhim Zahawi
Read full article
Oops!
The UK is getting safer every day as almost one in five adults have now had their first dose of the coronavirus vaccine, Nadhim Zahawi has said.
The NHS is on track to meet its target of vaccinating the top four priority groups by mid-February through a close focus on the most vulnerable , the vaccines minister told MPs.
More than nine in 10 people over the age of 80 have now had their first dose of the vaccine, as have nine in 10 over-75s and over half of all over-70s.